MAGE A1-A6 RT-PCR and MAGE A3 and p16 methylation analysis in induced sputum from patients with lung cancer and non-malignant lung diseases

Shin,Kyeong-Cheol; Lee,Kwan-Ho; Lee,Chae-Hun; Shin,Im-Hee; Suh,Hun-Suk; Jeon,Chang-Ho

doi:10.3892/or.2011.1566

MAGE A1-A6 RT-PCR and MAGE A3 and p16 methylation analysis in induced sputum from patients with lung cancer and non-malignant lung diseases

Authors:
- Kyeong-Cheol Shin
- Kwan-Ho Lee
- Chae-Hun Lee
- Im-Hee Shin
- Hun-Suk Suh
- Chang-Ho Jeon
View Affiliations

Affiliations: Department of Internal Medicine, Yeungnam University, Daegu, Republic of Korea, Department of Laboratory Medicine, College of Medicine, Catholic University of Daegu, 3056-6 Daemyung 4-Dong, Nam-gu, Daegu 705-718, Republic of Korea
Published online on: November 29, 2011 https://doi.org/10.3892/or.2011.1566
Pages: 911-916
Copyright: © Shin et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The melanoma antigen gene (MAGE) A1-A6 RT-PCR system was developed for the detection of lung cancer cells in the sputum. However, we identified MAGE expression in some patients with non-malignant lung diseases. To understand these patterns of MAGE expression, we performed MAGE A3 methylation-specific PCR (MSP) and p16 MSP. We collected 24 biopsy specimens of lung cancer tissue and performed MAGE A1-A6 RT-PCR, MAGE A3 MSP and p16 MSP. RNA and DNA were simultaneously extracted from induced sputum specimens of 133 patients with lung diseases and 30 random sputum specimens of healthy individuals and the 3 molecular analyses were performed. The patients were diagnosed as 65 cases of lung cancer and 68 of benign lung diseases. Positive rates of MAGE A1-A6 RT-PCR, MAGE A3 MSP and p16 MSP were as follows: in lung cancer tissue, 87.5, 58.3 and 70.8%; in the sputum of lung cancer patients, 50.8, 46.2 and 63.1%; benign lung diseases, 10.3, 30.9 and 39.7%; and healthy individuals, 3.3, 6.7 and 3.3%. Of the 40 MAGE-positive cases, 33 were diagnosed with lung cancer and 7 as having benign lung diseases. From the 7 cases of MAGE-positive benign lung diseases, 6 cases showed methylation abnormalities. The MAGE-positive group revealed significantly higher rates of methylation abnormalities. Of the 40 MAGE-positive cases, 39 cases were found to be lung cancer or benign lung diseases with abnormal methylation. Thus, MAGE expression in the sputum suggests the presence of lung cancer cells or pre-cancerous cells.

View Figures

View References

1	Park JW, Kwon TK, Kim IH, et al: A new strategy for the diagnosis of MAGE-expressing cancers. J Immunol Methods. 266:79–86. 2002. View Article : Google Scholar : PubMed/NCBI
2	Jheon S, Hyun DS, Lee SC, et al: Lung cancer detection by a RT-nested PCR using MAGE A1-6 common primers. Lung Cancer. 43:29–37. 2004. View Article : Google Scholar : PubMed/NCBI
3	Jang SJ, Soria JC, Wang L, et al: Activation of melanoma antigen tumor antigens occurs early in lung carcinogenesis. Cancer Res. 61:7959–7963. 2001.PubMed/NCBI
4	van der Bruggen P, Traversari C, Chomez P, et al: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 254:1643–1647. 1991.
5	De Plaen E, Arden K, Traversari C, et al: Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics. 40:360–369. 1994.PubMed/NCBI
6	Mecklenburg I, Stratakis DF, Huber RM, et al: Detection of melanoma antigen-A expression in sputum and bronchial lavage fluid of patients with lung cancer. Chest. 125:164S–166S. 2004. View Article : Google Scholar : PubMed/NCBI
7	Chaturvedi AK, Gaydos CA, Agreda P, et al: Chlamydia pneumoniae infection and risk for lung cancer. Cancer Epidemiol Biomarkers Prev. 19:1498–1505. 2010. View Article : Google Scholar
8	Pastorino U: Lung cancer screening. Br J Cancer. 102:1681–1686. 2010. View Article : Google Scholar
9	Anglim PP, Alonzo TA and Laird-Offringa IA: DNA methylation-based biomarkers for early detection of non-small cell lung cancer: an update. Mol Cancer. 7:812008. View Article : Google Scholar : PubMed/NCBI
10	Yasufuku K: Early diagnosis of lung cancer. Clin Chest Med. 31:39–47. 2010. View Article : Google Scholar
11	Sienel W, Varwerk C, Linder A, et al: Melanoma associated antigen (MAGE)-A3 expression in stages I and II non-small cell lung cancer: results of a multi-center study. Eur J Cardiothorac Surg. 25:131–134. 2004. View Article : Google Scholar : PubMed/NCBI
12	Atanackovic D, Altorki NK, Cao Y, et al: Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming. Proc Natl Acad Sci USA. 105:1650–1655. 2008. View Article : Google Scholar : PubMed/NCBI
13	Tsuji T, Altorki NK, Ritter G, et al: Characterization of preexisting MAGE-A3-specific CD4⁺ T cells in cancer patients and healthy individuals and their activation by protein vaccination. J Immunol. 183:4800–4808. 2009.PubMed/NCBI
14	Risch A and Plass C: Lung cancer epigenetics and genetics. Int J Cancer. 123:1–7. 2008. View Article : Google Scholar : PubMed/NCBI
15	Kim H, Kim SJ, Lee SH, et al: Usefulness of melanoma antigen (MAGE) gene analysis in tissue samples from percutaneous needle aspiration biopsy of suspected lung cancer lesions. Lung Cancer. 69:284–288. 2010. View Article : Google Scholar : PubMed/NCBI
16	Zheng W, Blot WJ, Liao ML, et al: Lung cancer and prior tuberculosis infection in Shanghai. Br J Cancer. 56:501–504. 1987. View Article : Google Scholar : PubMed/NCBI
17	Kurasawa T: The coexistence of pulmonary tuberculosis and lung cancer. Nihon Rinsho. 56:3167–3170. 1998.PubMed/NCBI
18	Olaussen KA, Soria JC, Park YW, et al: Assessing abnormal gene promoter methylation in paraffin-embedded sputum from patients with NSCLC. Eur J Cancer. 41:2112–2119. 2005. View Article : Google Scholar : PubMed/NCBI
19	Kim YT, Lee SH, Sung SW, et al: Can aberrant promoter methylation of CpG islands predict the clinical outcome of non-small cell lung cancer after curative resection? Ann Thorac Surg. 79:1180–1188. 2005. View Article : Google Scholar : PubMed/NCBI
20	Kim DS, Cha SI, Lee JH, et al: Aberrant DNA methylation profiles of non-small cell lung cancers in a Korean population. Lung Cancer. 58:1–6. 2007. View Article : Google Scholar : PubMed/NCBI
21	Ulivi P, Zoli W, Calistri D, et al: p16INK4A and CDH13 methylation in tumor and serum of non-small cell lung cancer patients. J Cell Physiol. 206:611–615. 2006. View Article : Google Scholar : PubMed/NCBI
22	Liu Y, An Q, Li L, et al: Methylation of p16INK4a in Chinese lung cancer patients: biological and clinical implications. Carcinogenesis. 24:1897–1901. 2003. View Article : Google Scholar : PubMed/NCBI
23	Hsu HS, Chen TP, Wen CK, et al: Multiple genetic and epigenetic biomarkers for lung cancer detection in cytologically negative sputum and a nested case-control study for risk assessment. J Pathol. 213:412–419. 2007. View Article : Google Scholar : PubMed/NCBI
24	Yang B, O'Herrin SM, Wu J, et al: MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positive cell lines. Cancer Res. 67:9954–9962. 2007. View Article : Google Scholar : PubMed/NCBI
25	Jeon CH, Shin IH, Park JB, et al: Prognostic significance of MAGE in peritoneal washes in gastric carcinoma patients without peritoneal metastasis: results of a 5-year follow-up study. J Clin Gastroenterol. 44:682–686. 2010.PubMed/NCBI